BACKGROUND: Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti-CD20 monoclonal antibody, has shown activity and an acceptable safety profile when combined with CHOP (G-CHOP) in patients with advanced DLBCL. We present the final analysis results of the Phase III GOYA study (NCT01287741), which compared the efficacy and safety of G-CHOP versus R-CHOP in patients with previously untreated DLBCL. METHODS: Patients aged ≥ 18 years with previously untreated advanced DLBCL were randomly assigned to receive eight 21-day cycles of R or G, plus six or eight cycles of CHOP. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival, other time-to-event endpoints, and safety; investigator-assessed PFS by cell of origin subgroup was an exploratory endpoint. RESULTS: A total of 1418 patients were randomized, with 1414 included in this final analysis (G-CHOP, N = 704; R-CHOP, N = 710). Five-year PFS rates were 63.8% and 62.6% for G-CHOP and R-CHOP, respectively (stratified hazard ratio 0.94, 95% CI 0.78-1.12; p = 0.48). The results of the secondary efficacy endpoints did not show a benefit of G-CHOP over R-CHOP. In the exploratory analysis, a trend towards benefit with G-CHOP over R-CHOP was apparent in the patients with germinal center B cell DLBCL. The safety profile of G-CHOP was as expected, and no new safety signals were observed. More grade 3-5 (75.1% vs 65.8%), serious (44.4% vs 38.4%), and fatal (6.1% vs 4.4%) adverse events (AEs) were observed in the G-CHOP arm compared with the R-CHOP arm, respectively, with the most common fatal AEs being infections. A higher incidence of late-onset neutropenia occurred in the G-CHOP arm (8.7%) versus the R-CHOP arm (4.9%). CONCLUSIONS: The final analysis, similar to the primary analysis, did not show a PFS benefit of G-CHOP over R-CHOP in previously untreated patients with DLBCL. The results of the secondary endpoints were consistent with the primary endpoint. Further exploratory analyses and investigation of biomarkers are ongoing.

BC Cancer Centre for Lymphoid Cancer and the University of British Columbia Vancouver BC Canada

Candiolo Cancer Institute FPO IRCCS Candiolo Italy

Charles University General Hospital Prague Czech Republic

Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy

F Hoffmann La Roche Ltd Basel Switzerland

Genentech Inc South San Francisco CA USA

Roche Pharma Development Shanghai China

000      

00000naa a2200000 a 4500

001      

bmc21020464

003      

CZ-PrNML

005      

20210830102133.0

007      

ta

008      

210728s2020 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1186/s13045-020-00900-7 $2 doi

035    __

$a (PubMed)32505213

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Sehn, Laurie H $u BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada. Lsehn@bccancer.bc.ca

245    12

$a A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA / $c LH. Sehn, M. Martelli, M. Trněný, W. Liu, CR. Bolen, A. Knapp, D. Sahin, G. Sellam, U. Vitolo

520    9_

$a BACKGROUND: Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti-CD20 monoclonal antibody, has shown activity and an acceptable safety profile when combined with CHOP (G-CHOP) in patients with advanced DLBCL. We present the final analysis results of the Phase III GOYA study (NCT01287741), which compared the efficacy and safety of G-CHOP versus R-CHOP in patients with previously untreated DLBCL. METHODS: Patients aged ≥ 18 years with previously untreated advanced DLBCL were randomly assigned to receive eight 21-day cycles of R or G, plus six or eight cycles of CHOP. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival, other time-to-event endpoints, and safety; investigator-assessed PFS by cell of origin subgroup was an exploratory endpoint. RESULTS: A total of 1418 patients were randomized, with 1414 included in this final analysis (G-CHOP, N = 704; R-CHOP, N = 710). Five-year PFS rates were 63.8% and 62.6% for G-CHOP and R-CHOP, respectively (stratified hazard ratio 0.94, 95% CI 0.78-1.12; p = 0.48). The results of the secondary efficacy endpoints did not show a benefit of G-CHOP over R-CHOP. In the exploratory analysis, a trend towards benefit with G-CHOP over R-CHOP was apparent in the patients with germinal center B cell DLBCL. The safety profile of G-CHOP was as expected, and no new safety signals were observed. More grade 3-5 (75.1% vs 65.8%), serious (44.4% vs 38.4%), and fatal (6.1% vs 4.4%) adverse events (AEs) were observed in the G-CHOP arm compared with the R-CHOP arm, respectively, with the most common fatal AEs being infections. A higher incidence of late-onset neutropenia occurred in the G-CHOP arm (8.7%) versus the R-CHOP arm (4.9%). CONCLUSIONS: The final analysis, similar to the primary analysis, did not show a PFS benefit of G-CHOP over R-CHOP in previously untreated patients with DLBCL. The results of the secondary endpoints were consistent with the primary endpoint. Further exploratory analyses and investigation of biomarkers are ongoing.

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000971

650    _2

$a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $7 D003520

650    _2

$a doxorubicin $x aplikace a dávkování $x škodlivé účinky $7 D004317

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a Kaplanův-Meierův odhad $7 D053208

650    _2

$a difúzní velkobuněčný B-lymfom $x farmakoterapie $7 D016403

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a prednison $x aplikace a dávkování $x škodlivé účinky $7 D011241

650    _2

$a doba přežití bez progrese choroby $7 D000077982

650    _2

$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283

650    _2

$a vinkristin $x aplikace a dávkování $x škodlivé účinky $7 D014750

650    _2

$a mladý dospělý $7 D055815

655    _2

$a klinické zkoušky, fáze III $7 D017428

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Martelli, Maurizio $u Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

700    1_

$a Trněný, Marek $u Charles University General Hospital, Prague, Czech Republic

700    1_

$a Liu, Wenxin $u Roche Pharma Development, Shanghai, China

700    1_

$a Bolen, Christopher R $u Genentech, Inc., South San Francisco, CA, USA

700    1_

$a Knapp, Andrea $u F. Hoffmann-La Roche Ltd, Basel, Switzerland

700    1_

$a Sahin, Deniz $u F. Hoffmann-La Roche Ltd, Basel, Switzerland

700    1_

$a Sellam, Gila $u F. Hoffmann-La Roche Ltd, Basel, Switzerland

700    1_

$a Vitolo, Umberto $u Candiolo Cancer Institute, FPO-IRCCS, (Turin), Candiolo, Italy

773    0_

$w MED00165458 $t Journal of hematology & oncology $x 1756-8722 $g Roč. 13, č. 1 (2020), s. 71

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32505213 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210728 $b ABA008

991    __

$a 20210830102133 $b ABA008

999    __

$a ok $b bmc $g 1691102 $s 1140910

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 13 $c 1 $d 71 $e 20200606 $i 1756-8722 $m Journal of hematology & oncology $n J Hematol Oncol $x MED00165458

LZP    __

$a Pubmed-20210728